BioMarin Pharmaceutical Inc.

ROCTAVIAN

Manufacturer:

BioMarin Pharmaceutical Inc.

Roctavian HCPCS:

J1412

HCPCS Code Descriptor:

Injection, valoctocogene roxaparvovec-rvox, per ml, containing nominal 2 x 10^13 vector genomes

Category:

J Code

Roctavian NDCs:

68135-0927-48

Primary Type:

Hematology

Generic/Specialty Status:

Single-Source

Route of Administration:

Intravenous

Potential NDC Listing Errors:

Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.

About Roctavian:

ROCTAVIAN is a Hematology drug manufactured by BioMarin Pharmaceutical Inc. and administered via the Intravenous route of administration. The J Code: J1412 is aligned to the drug ROCTAVIAN.

Roctavian is used to treat Hemophilia A, a blood clotting disease. Hemophilia A is a genetic disorder. People with hemophilia A either lack a certain blood clotting protein, or have clotting proteins that don't work properly. This can cause uncontrollable bleeding. Roctavian is a type of gene therapy. It works by helping your body produce normal clotting proteins.

ACCESS PRICING AND MORE BY REGISTERING

J1412 Added Date:

January 1, 2024

J1412 Effective Date:

January 1, 2024

J1412 Termination Date:

HCPCS Active

Roctavian billing and coding information can be found through Biomarin Pharmaceutical Inc. at the link below:
Roctavian patient assistance information can be found through Biomarin Patient Support at the URL: https://www.roctavian.com/en-us/biomarin-patient-support/
ROCTAVIAN prescribing information can be found at the link below:
Information regarding ROCTAVIAN’s side effects can be found at MedlinePlus